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Abstract
Background: Canine babesiosis is a tick-borne disease caused by hemoprotozoan parasites of the genus Babesia.
The disease can be clinically classified into uncomplicated and complicated forms. The aim of this study was to
assess the level of endothelial activation and alterations in the fibrinolytic pathway during canine babesiosis.
Results: Blood samples were collected on the day of admission and on the 6th day after treatment with imidocarb
propionate, from 30 dogs of various breeds and of both sexes with naturally occurring babesiosis caused by B.
canis. In this prospective study, plasminogen activity was assessed using a chromogenic assay, and concentrations
of high mobility group box-1 protein (HMGB-1), intercellular adhesive molecule-1 (ICAM-1), vascular adhesive
molecule-1 (VCAM-1), soluble urokinase receptor of plasminogen activator (suPAR), thrombin activatable fibrinolysis
inhibitor (TAFI), soluble thrombomodulin (TM) and plasminogen activator inhibitor-1 (PAI-1) were determined using
a canine specific ELISA. Concentrations of TM, HMGB-1, VCAM-1 and suPAR were increased in dogs with babesiosis
at admission compared to healthy dogs. After treatment, concentrations of TM were lower in infected dogs
compared to healthy dogs. Dogs with babesiosis also had increased concentrations of TM, ICAM-1 and HMGB-1
and decreased plasminogen and PAI-1 at presentation compared to day 6 after treatment. Dogs with complicated
babesiosis had higher concentrations of TM, HMGB1 and TAFI at admission compared to the 6th day.
Conclusions: Biomarkers of endothelial activation and fibrinolysis were altered in dogs with babesiosis. Further
studies into their usefulness as biomarkers of disease severity or prognosis is warranted.
Keywords: Biomarkers, Hemostasis, Vascular Endothelium
Background
Canine babesiosis is a tick-borne disease caused by hemo-
protozoan parasites of the genus Babesia [1]. Three main
species of large Babesia infect dogs, namely B. vogeli, B.
canis and B. rossi [2]. The disease can be clinically
classified into uncomplicated and complicated forms with
a wide range of clinical presentations from a mild, subclinical
illness to complicated forms and death [3].
Inflammation and hemostasis are tightly interrelated
pathophysiologic processes that may affect each other
considerably. Extensive crosstalk between immune and
hemostatic systems occurs at the level of all components
of the hemostatic system, including vascular endothelial
cells, platelets, plasma coagulation cascade, physiologic
anticoagulant pathways and fibrinolytic activity [4]. The
presence of hemostatic abnormalities [5–8] and alter-
ations in the inflammatory response [9–11] are well
documented in canine babesiosis. However, whether
there are alterations in the fibrinolytic system has not
been previously examined.
Endothelial cell activation can be damaging if it is
uncontrolled, persistent or widespread [12]. Endothelial
dysfunction contributes to the pathogenesis of a variety
of potentially serious infectious diseases and syndromes
[13]. The vascular endothelium has an important role in
the pathogenesis of canine babesiosis [6]. Differential cell
surface molecule expression between quiescent and acti-
vated endothelial cells influences the degree of adhesion
of circulating blood cells, as well as the relative balance
between pro- and anti-coagulant activity [14]. Given
their specificity for endothelial cells in the activated
state, the soluble forms of cell-surface molecules, shed
from endothelial cells after activation, have been widely
studied as diagnostic and prognostic markers in a variety
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of infectious diseases. Intercellular adhesive molecule-1
(ICAM-1) mediates the firm adhesion of leukocytes to
the endothelium and the subsequent transmigration to
inflammatory sites, while vascular adhesive molecule-1
(VCAM-1) contributes to the adhesion of activated
lymphocytes and monocytes to endothelial cells in acute
inflammatory tissues [15]. Thrombomodulin (TM) is a
an endothelial receptor that prevents dissemination of
pro-coagulant and proinflammatory molecules, and by
doing so, allows these molecules to act locally at the site
of injury [16]. TM promotes thrombin-mediated activa-
tion of protein C and is essential for thrombin activata-
ble fibrinolysis inhibitor (TAFI) activation. High mobility
group box-1 protein (HMGB-1) is a highly conserved
component of eukaryotic nuclei and is known as a DNA
binding protein [17]. HMGB-1 is actively secreted by
certain inflammatory cells and endothelial cells, and is
passively released by necrotic or damaged cells [18].
Once released into the intravascular space, HMGB1
amplifies local inflammatory responses by enhancing the
release of cytokines and chemokines from monocytes-
macrophages and interacts with endothelial cells by up-
regulating surface receptors and inducing the secretion
of soluble proinflammatory mediators [19].
Components of the fibrinolytic system are mainly
synthesized in the vascular endothelium and distur-
bances in vascular endothelium may induce an imbal-
ance in fibrinolysis. Plasmin, as a result of plasminogen
activation by plasminogen activators, cleaves fibrin and
other important components of blood clots by initiating
a proteolytic cascade leading to fibrinolysis and thromb-
olysis [20]. Tissue plasminogen activator (tPA) and
urokinase plasminogen activator (uPA) are the most im-
portant mediators of plasminogen activation. Inhibition
of the fibrinolytic system may occur at the level of plas-
minogen activation, mainly by a specific plasminogen
activator inhibitor 1 (PAI-1) or by thrombin-activatable
fibrinolysis inhibitor (TAFI), and at the level of plasmin,
mainly by α2-antiplasmin [21]. It has been shown that
bacteria, viruses and parasites utilise the plasminogen
activation system for their biological needs [22–25].
It has been reported that a proinflammatory state occurs
in babesiosis that is associated with increased concentra-
tions of markers of endothelial cell activation and altered
hemostasis [6, 26]. Because canine babesiosis could be
accompanied by endothelial dysfunction, the relationship
between endothelial function and fibrinolytic balance
needs to be examined in more detail. Biomarkers of acti-
vated endothelium might indicate increased endothelial
dysfunction during canine babesiosis. Our overall hypoth-
esis is that markers of endothelial cell activation and alter-
ations in fibrinolysis are increased in dogs with babesiosis
and that these markers may be useful in monitoring
disease progression. The specific aims of this study were:
i) to determine whether markers of endothelial cell activa-
tion and fibrinolytic activity are different in dogs infected
with B. canis at the time of diagnosis (day 0) and 6 days
after imidocarb treatment, compared to healthy controls;
ii) whether there are differences on day 0 compared with
day 6 among infected dogs; iii) and whether there are
differences between dogs with complicated and uncompli-
cated infection.
Methods
Animals
Blood samples were collected from 30 dogs of various
breeds and of both sexes with naturally occurring
babesiosis caused by B. canis, who were admitted to the
Internal Diseases Clinic, Faculty of Veterinary Medicine,
University of Zagreb, Croatia. This study was approved by
the Committee on the Ethics of the University of Zagreb,
Faculty of Veterinary Medicine. There were 12 females
and 18 males, aged from 2 months to 10 years (median,
interquartile range: 24 months, 11–60 months). Half of all
dogs were mixed breed, and additionally there were 4
Labrador Retrievers, 2 Golden Retrievers, 2 American
Staffordshire Terriers, and one Croatian Sheepdog, Alpine
Dachsbracke, German Shepard, Doberman, Siberian
Husky, Irish Red Setter and Alaskan Malamute. The diag-
nosis of babesiosis was confirmed by demonstration of the
parasites within the infected erythrocytes in thin blood
smears stained with May-Grünwald-Giemsa stain. Species
were confirmed using PCR, as described previously [8].
One dose (6 mg/kg) of imidocarb dipropionate (Imizol®
12%, Schering-Plough, Kenilworth, NJ, USA) was adminis-
tered to all the dogs subcutaneously on the day of admis-
sion. As needed, other supportive therapy was given
mostly to dogs with complicated babesiosis. Supportive
therapy included 0.9% saline solution and metoclopramide
to treat nausea and vomiting. No reference was found about
possible effects of this supportive therapy on endothelium
function or fibrinolysis, except changes in hematocrit as
consenquence of fluid compensation. Therefore we hypothe-
sised that these differences in treatment among dogs didn’t
have significant effect on investigated parameters. Blood was
collected on the day of admission (B0), and on the 6th day
(B6) of treatment.
The control group consisted of 10 healthy dogs. At the
time of enrollment, none of the healthy dogs had histor-
ies of previous illness. Routine hematologic and bio-
chemical analysis with urianalysis were performed, and
all of the obtained results were within reference ranges.
PCR was performed as for infected dogs, to rule out
sublinical infection. All dogs were mixed breed, aged
from 2 to 10 years, 6 of them were males and 4 females.
Serum samples from dogs with babesiosis and healthy
dogs were screened for simultaneous qualitative detec-
tion of circulating D. immitis antigen and antibodies,
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both immunoglobulin G and M, to E. canis, B. burgdorferi
sensu lato and A. phagocytophilum with the SNAP®4Dx®
test (IDEXX Laboratories, Westbrook, Maine, USA) and
antibodies to L. infantum with the SNAP Leishmania test
(IDEXX Laboratories). Dogs with evidence of coinfection
were excluded from the study.
On the basis of clinical manifestations and laboratory
data (hematologic and biochemical analysis with urianaly-
sis) at admission, the affected dogs were divided into two
groups, complicated (N = 11) and uncomplicated (N = 19)
babesiosis. An animal was classified as complicated if one
of the following criteria were fulfilled [27]: renal dys-
function (serum creatinine concentration of more than
155 μmol/L in the absence of pre-renal azotemia), hep-
atic involvement (both alanine aminotransferase (ALT)
greater than 176 U/L and alkaline phosphatase (AP)
greater than 360 U/L), central nervous system dysfunc-
tion (a score on the modified Glasgow coma scale of
less than 9), respiratory system dysfunction (radio-
graphic evidence of pulmonary oedema, or increased
effort to breathe), pancreatic dysfunction (all samples
with increased amylase and lipase values in our lab are
routinely checked by IDEXX SNAP cPL test for canine
pancreas-specific lipase) and muscular involvement (creat-
ine phosphokinase (CPK) more than 600 U/L). The noted
complications were muscular involvement (7/11 dogs),
respiratory system dysfunction (4/11), pancreatic dysfunc-
tion (1/11) and hepatic dysfunction (1/11).
Sample analysis
Blood was collected by jugular venipuncture, using the
Vacutainer blood collection system (Becton, Dickinson
and Co., Rutherford, NJ). Blood samples were drawn
atraumatically into EDTA and trisodium citrate tubes.
EDTA plasma was separated by centrifugation at 1000 ×
g at 4 °C for 15 min, within 1 h of collection, and
citrated plasma by centrifugation at 2000 × g at 4 °C for
15 min. Aliquots of plasma were stored at −80 °C for 2
to 8 months before analysis. Previous studies showed
stability of fibrinolytic variables, soluble cell adhesion
molecules and endothelial markers after long-time storage
at −80 °C [28–30]. Concentrations of HMGB-1, ICAM-1,
VCAM-1, soluble urokinase receptor of plasminogen
activator (suPAR) and TAFI were measured in EDTA
plasma, while concentrations of TM, PAI-1 and plasminogen
(PLG) activity were measured in citrate plasma.
Plasminogen activity was assessed using a chromo-
genic substrate test on the ACL 7000 analyzer (Instru-
mentation Laboratory, Milan, Italy) using reagents from
that manufacturer. The assay was calibrated using a pool
from 10 clinically healthy dogs. Canine-specific ELISA
kits were used for following analytes: TM, ICAM-1, and
HMGB-1 (USCN Life Science, Wuhan, China), PAI-1
(Blue Gene Biotech, Shanghai, China), and VCAM-1,
TAFI and suPAR (Biotang Source International, Camarillo,
USA). For ELISA analyses, intra-assays precision were
CV < 10%, and inter-assays CV < 12%, while spike-recovery
were 92–107%, according to the manufacturers.
ICAM-1 correction
For any given quantity (ng) of soluble ICAM-1 in the
circulating blood, anemic animals will distribute that
amount over a larger volume of plasma compared with
non-anemic animals, resulting in a lower measured
plasma concentration. To correct for anemia the follow-
ing formula was applied for all samples to convert the
measured plasma concentration of ICAM-1 to the
concentration expected in whole blood [31]:
Blood ICAM1 ðng=mL bloodÞ
¼ ðplasma ICAM1 ðng=ml plasmaÞÞ
 ð1Hct=%Þ;
where Hct stands for hematocrit.
Statistical analysis
Statistical analysis was performed using the statistical
computer application, Statistica 8 (StatSoft Inc., Tulsa,
OK). Distribution of data was tested by Kolmogorov-
Smirnov test. Differences between healthy and diseased
dogs were assessed by t-test for normally distributed
data, and Mann-Whitney U-test for nonparametric data.
Wilcoxon matched pairs test and dependent t-test were
used to access differences between dependent samples
(dogs with babesiosis at admission and on the 6th day).
Spearmans rank test was used to access correlations.
Differences with a P-value <0.05 were considered statis-
tically significant.
Results
Markers for endothelial activation, such as TM, HMGB-1
and VCAM-1, were significantly increased in dogs with
babesiosis at admission compared to healthy dogs
(Table 1). Comparing day 0 and day 6, increased concen-
trations of TM, ICAM-1 and HMGB-1 were found on day
0. On day 6, concentrations of TM were decreased com-
pared to healthy dogs. In case of fibrinolysis markers,
suPAR was significantly increased in dogs with babesiosis
at admission compared to healthy dogs, while PLG activity
and PAI-1 concentration were decreased compared to
day 6.
Markers for endothelial activation, such as TM and
HMGB1, were significantly increased in dogs with compli-
cated babesiosis at admission compared to day 6, while
compared to dogs with uncomplicated babesiosis VCAM-
1 was increased. Dogs with uncomplicated babesiosis on
day 0 had higher TM, ICAM-1 and HMGB1 concentra-
tions compared to day 6. In case of fibrinolysis markers,
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dogs with complicated babesiosis had higher concentra-
tions of TAFI at admission compared to day 6, as well as
compared to dogs with uncomplicated babesiosis, while
dogs with uncomplicated babesiosis on day 0 had lower
PAI-1 concentrations and plasminogen activity compared
to day 6 (Tables 2 and 3).
Correlations between parameters in dogs naturally
infected with Babesia canis at admission and on day 6
are presented in Table 4. Significant correlations were
found between HMGB-1 and ICAM-1, PAI-1 and
ICAM-1 on day 0 and 6, between PAI-1 and TM on day 0,
and between TAFI and TM on day 6.
Discussion
In this study, markers of endothelial activation were
found to be increased in dogs with babesiosis at admis-
sion compared to healthy dog controls (TM, HMGB-1
and VCAM-1) and compared to day 6 of treatment
(TM, ICAM-1, and HMGB-1), as well as between dogs
with complicated and uncomplicated babesiosis (TM,
HMGB1, ICAM-1, and VCAM-1). Fibrinolysis markers
were also altered in dogs with babesiosis at admission
compared to healthy dog controls (suPAR), and com-
pared to day 6 (PLG and PAI-1), as well as between dogs
with complicated and uncomplicated babesiosis (PAI-1
and TAFI).
HMGB-1 has been shown to play a key role in the
pathogenesis of inflammatory and autoimmune diseases in
humans [32]. As a proinflammatory mediator, HMGB-1
induces expression of two key adhesion molecules, ICAM-
1 and VCAM-1 [19]. A few reports are available on blood
HMGB-1 concentrations in veterinary medicine, including
dogs with systemic inflammatory response syndrome and
dogs with lymphoma and canine prostate cancer [33–35].
In this study, concentrations of plasma HMGB-1 were in-
creased in dogs with babesiosis compared to healthy dogs
Table 1 Concentrations of blood markers of fibrinolysis and endothelial activation in canine babesiosis
Parameter (unit) Group N Mean ± SD / Median (interquartile range) P value* B0-B6 P value** B0 - C P value*** B6 - C
TM (ng/ml) B0 30 3.53 (2.65–4.25) <0.001 0.001 0.009
B6 30 1.47 (1.31–1.78)
Control 10 1.98 (1.62–2.41)
ICAM-1 (ng/ml) B0 30 6.75 (5.07–10.19) 0.007 0.866 0.636
B6 28 6.42 (4.44–9.91)
Control 10 7.59 (4.6–18.7)
HMGB-1 (ng/ml) B0 30 47.88 (34.12–88.1) <0.001 <0.001 0.524
B6 28 17.59 (12.33–43.88)
Control 10 15.71 (13.27–26.0)
PLG (%) B0 30 85.5 (82.0–105.0) 0.011 0.053 0.906
B6 27 103.0 (92.0–131.0)
Control 10 104.0 (96.0–111.0)
PAI-1 (pg/ml) B0 30 184.1 (92.67–405.96) 0.036 0.054 0.272
B6 28 324.06 (176.59–608.05)
Control 10 413.05 (371.78–540.97)
TAFI (ng/ml) B0 30 461.15 ± 80.80 0.072 0.795 0.217
B6 26 511.91 ± 140.65
Control 10 453.92 ± 55.93
suPAR (pg/ml) B0 30 4311.63 (3893.05–4840.3) 0.091 0.001 0.520
B6 26 3725.3 (3277.2–4673.55)
Control 10 3613.35 (3052.65–3893.05)
VCAM-1 (ng/ml) B0 30 480.66 ± 59.21 0.841 0.026 0.056
B6 29 478.44 ± 74.09
Control 10 416.73 ± 113.4
Concentrations of soluble thrombomodulin (TM), soluble intercellular adhesive molecule-1 (ICAM-1), high mobility group box-1 protein (HMGB-1), plasminogen
(PLG), plasminogen activator inhibitor-1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI), soluble urokinase receptor of plasminogen activator (suPAR) and
soluble vascular adhesive molecule-1 (VCAM-1) in dogs with babesiosis at admission (B0), on the 6th day (B6) and healthy dogs (Control)
*P value for differences between dependent samples on the day 0 and 6 (Wilcoxon matched pairs test and dependent t-test)
**P value for differences between dogs with babesiosis day 0 compared to control (Mann-Whitney and t-test)
***P value for differences between dogs with babesiosis day 6 compared to control (Mann-Whitney and t-test)
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at admission, as well as on day 6 after treatment.
Concentrations of VCAM-1 were increased in dogs
with babesiosis at admission compared to healthy
dogs, while ICAM-1 concentrations were increased in
dogs with babesiosis at admission compared to day 6.
An increase of ICAM-1 compared to healthy dogs
was reported previously in canine babesiosis [6]. Dogs with
complicated babesiosis at admission had higher concentra-
tions of VCAM-1 compared to dogs with uncomplicated
babesiosis. Expression levels of soluble adhesion molecules
are also increased in animal models of sepsis [36, 37].
In malaria, increased margination and sequestration
Table 2 Concentrations of blood markers of endothelial activation in complicated (CB) and uncomplicated (UB) canine babesiosis
Parameter (unit) Group N Median (interquartile range) P value
(UB 0 – CB 0)
P value
(UB 0 – UB 6)
P value
(CB 0 – CB 6)
P value
(UB 6 – CB 6)
TM (ng/ml) UB, day 0 19 3,77 (2,02–4,58) 0,933 <0,001 0,003 0,471
CB, day 0 11 3,45 (3,13–4,09)
UB, day 6 19 1,55 (1,23–1,94)
CB, day 6 11 1,39 (1,31–1,55)
ICAM-1 (ng/ml) UB, day 0 19 6,96 (4,95–10,19) 0,832 0,002 0,575 0,174
CB, day 0 11 6,46 (5,07–11,34)
UB, day 6 18 6,24 (3,76–8,09)
CB, day 6 10 6,69 (4,94–47,68)
HMGB-1 (ng/ml) UB, day 0 19 44,93 (34,12–109,49) 0,899 <0,001 0,022 0,869
CB, day 0 11 50,84 (29,31–88,1)
UB, day 6 18 19,89 (12,73–37,34)
CB, day 6 10 15,5 (10,52–73,25)
VCAM-1 (ng/ml) UB, day 0 19 451,25 (429,2–507,4) 0,004 0,199 0,093 0,247
CB, day 0 11 489,6 (476,3–576,05)
UB, day 6 19 494,05 (432,15–547,6)
CB, day 6 10 471,88 (417,45–489,6)
TM soluble thrombomodulin, ICAM-1 soluble intercellular adhesive molecule-1, HMGB-1 high mobility group box-1 protein, VCAM-1 soluble vascular adhesive molecule-1
Table 3 Concentrations and activity of blood markers of fibrinolysis in complicated (CB) and uncomplicated (UB) canine babesiosis
Parameter (unit) Group N Median (interquartile range) P value
(UB 0 – CB 0)
P value
(UB 0 – UB 6)
P value
(CB 0 – CB 6)
P value
(UB 6 – CB 6)
PLG (%) UB, day 0 19 85,0 (81,5–98,0) 0,517 0,019 0,169 0,789
CB, day 0 11 92,5 (83,0–114,0)
UB, day 6 16 101,0 (91,5–125,5)
CB, day 6 11 104,0 (92,0–131,0)
PAI-1 (pg/ml) UB, day 0 19 255,49 (96,81–519,27) 0,445 0,031 0,594 0,059
CB, day 0 11 148,19 (75,1–323,52)
UB, day 6 17 392,92 (321,44–700,34)
CB, day 6 11 230,09 (117,59–309,24)
TAFI (ng/ml) UB, day 0 19 481,1 (417,55–538,7) 0,232 0,877 0,037 0,020
CB, day 0 11 440,7 (388,6–481,1)
UB, day 6 16 455,15 (397,3–518,58)
CB, day 6 10 561,6 (475,35–693,45)
suPAR (pg/ml) UB, day 0 19 4283,75 (3893,05–4729,15) 0,553 0,179 0,333 0,979
CB, day 0 11 4450,9 (3893,05–5006,9)
UB, day 6 16 3725,3 (3305,23–4562,23)
CB, day 6 10 3697,33 (3164,95–5228,75)
PLG plasminogen, PAI-1 plasminogen activator inhibitor-1, TAFI thrombin activatable fibrinolysis inhibitor, suPAR soluble urokinase receptor of plasminogen activator
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of neutrophils is explained by the increased expres-
sion of cell adhesion molecules (ICAM-1 and VCAM-
1) [38]. This mechanism of neutropenia that has been
postulated for malaria might also be applied to the
neutropenia present in babesiosis [39]. An increase in
circulating adhesion molecules might either result from
increased cytokine-induced expression by endothelial
cells, increased proteolytic cleavage of endothelial-bound
adhesion molecules secondary to endothelial damage and/
or reduced soluble molecule clearance [40]. In this study,
a strong positive correlation between HMGB1 and ICAM-
1 (P < 0.05, r = 0.711) was found. Thus, the study suggests
that HMGB1 activates components necessary for recruit-
ment, adhesion, and transmigration of leukocytes across an
activated endothelium in babesiosis.
The fibrinolytic system plays a key role in maintenance
of vascular potency and thrombolysis by dissolving fibrin,
and it is also involved in several physiological and patho-
logical processes, such as local inflammatory reactions,
neoplastic invasion and tissue remodeling [20]. The
current study found lower plasminogen activity in dogs
with babesiosis at admission compared to activity on day
6 (P = 0.011). Various pathogens have plasminogen-
binding capacity, playing a role in the pathogenicity of
these agents. Plasminogen interaction with the surface of
various parasites or with their secreted molecules has been
shown [25]. Decreased plasminogen might therefore be
the result of its increased use by the parasite and/or
consumption due to the hypercoagulability reported in
babesiosis [7]. The latter is strengthened by the fact that
lower concentrations of fibrinolysis inhibitors, PAI-1 and
TAFI (only in complicated babesiosis), were found in dogs
with babesiosis at admission, followed by their increase on
the 6th day, so it can be proposed that inhibition of fibrin-
olysis may be impaired in dogs with babesiosis.
Thrombin-activatable fibrinolysis inhibitor (TAFI) is
the most recently discovered fibrinolysis inhibitor. TAFI
is activated by thrombin, the key component of the co-
agulation system, either free or in complex with TM
[41]. In dogs, TAFI activity has been described only in
experimental models of thrombosis [42, 43] and in stud-
ies in dogs with various spontaneous diseases [44].
Higher TAFI concentrations were found in dogs with
complicated babesiosis on day 6 compared to dogs with
uncomplicated babesiosis and also compared to dogs
with complicated babesiosis at admission. Low concen-
trations of TAFI at admission, together with low PLG
concentration, may suggest consumption from increased
fibrinolysis due to the hypercoagulable state present in
babesiosis cases. By day 6 the TAFI concentration had
returned to normal.
Concentrations of TM were increased in dogs with
babesiosis at admission compared to day 6 and com-
pared to healthy dogs, while on day 6, concentrations in
dogs with babesiosis were decreased compared to
healthy dogs. Increased concentration of soluble TM has
been proposed as both a diagnostic and prognostic
marker of endothelial activation [45]. One study found
Table 4 Correlation between parameters in dogs naturally infected with Babesia canis canis at admission (B0) and on the 6th day
(B6) (Spearman rank order) (*P < 0.05)
B0 TM ICAM-1 HMGB1 plg PAI-1 TAFI suPAR VCAM-1
TM 1.000 −0.086 −0.168 −0.030 0.394* −0.344 −0.180 0.328
ICAM-1 1.000 0.651* 0.199 0.430* −0.038 −0.142 −0.016
HMGB1 1.000 0.071 0.330 0.148 −0.049 −0.223
plg 1.000 0.277 −0.105 0.095 −0.056
PAI-1 1.000 −0.229 −0.106 0.174
TAFI 1.000 0.336 0.067
suPAR 1.000 0.107
VCAM-1 1.000
B6 TM ICAM-1 HMGB1 PLG PAI-1 TAFI suPAR VCAM-1
TM 1.000 −0.188 −0.200 0.284 −0.161 −0.439* 0.275 −0.384
ICAM-1 1.000 0.711* 0.087 0.689* 0.252 −0.039 −0.143
HMGB1 1.000 −0.082 0.383 0.359 −0.228 −0.253
PLG 1.000 0.081 −0.027 −0.027 −0.131
PAI-1 1.000 −0.097 0.035 −0.131
TAFI 1.000 −0.153 0.130
suPAR 1.000 0.102
VCAM-1 1.000
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that plasma TM concentrations were significantly higher
for dogs with leishmaniasis [46], especially those with
severe clinical signs, suggesting that TM can be used as
a non-invasive marker for endothelial activation in dogs.
In malaria, TM concentrations are increased with infec-
tion and decline with convalescence [38]. After treat-
ment, TM concentrations were also decreased in our
study. It is known that inflammatory cytokines and
elastase released from activated leukocytes reduce TM
expression and cleave the molecule when activation of
inflammatory processes takes place [47, 48], thus the
same mechanism is also possible in canine babesiosis.
Plasminogen activator inhibitor-1 (PAI-1) is a primary
physiological inhibitor of tPA and uPA [49]. Similarly to
TAFI, concentrations of PAI-1 were lower in dogs with
babesiosis at admission compared to day 6, with concen-
trations approaching normal values with time. These
findings contribute to documentation of fibrinolysis in-
hibitors consumption and increased fibrinolytic activity
in this study. Contrary to TAFI, changes in PAI-1 con-
centrations were more profound in uncomplicated cases
of babesiosis, probably due to faster resolution of endo-
thelial and hemostatic alterations than in complicated
babesiosis. The increase of PAI-1 during the course of
babesiosis could lead to suppression of fibrinolysis. This
study found a positive correlation between PAI-1 and
ICAM-1 (P < 0.05, r = 0.689) at both time points, dem-
onstrating an association between markers of endothelial
activation and fibrinolysis, showing that increased
expression of ICAM-1 and PAI-1 might be a result of
the proinflammatory state in babesiosis.
suPAR is a new and promising inflammatory bio-
marker for various infectious diseases in humans [50].
Dogs with babesiosis had a higher suPAR concentration
at admission compared to healthy dogs. In veterinary
medicine there are no studies on suPAR as a plasma
marker. There are only two studies of uPAR expression
in histological samples of the canine urinary tract and
prostate, where they found increased uPAR expression
in inflammatory and neoplastic tissue [51, 52]. Increased
suPAR concentrations have been reported in people with
viral, bacterial or parasitic infections, as well as with
autoimmune diseases [53]. A few studies on malaria in
people showed increased suPAR concentrations in
plasma and increased uPAR expression on endothelial
cells, suggesting that uPAR might be an additional
adhesion molecule for parasitised erythrocytes [54, 55].
The acute phase response in babesiosis is triggered by
the overproduction of inflammatory mediators and leads
to activation of the coagulation cascade and endothelial
activation [6], which might cause increased expression of
uPAR. Increased expression of uPAR on endothelial cells
may modulate vascular permeability as uPA binding and
plasmin generation at the surface of endothelial cells
induces loss of cell-cell contacts, retraction of endothelial
cells and increased permeability [56], all of which might
contribute to the pathogenesis of babesiosis. Finally, it has
been demonstrated that hypoxia stimulates uPAR-
expression on a protein and mRNA level in cultured
endothelial cells [57], suggesting that sequestration-
induced hypoxia, previously documented in babesiosis
[58, 59], could also contribute to high circulating suPAR
concentrations in babesiosis. Therefore, increased suPAR
concentrations in babesiosis may be a reflection of an
inflammatory response.
Conclusions
Biomarkers of endothelial activation and fibrinolysis were
altered in dogs with babesiosis. Markers of endothelial ac-
tivation are increased in babesiosis as a reflection of host
inflammatory response and shift the hemostatic activity
towards the procoagulant state. Decreased plasminogen
activity and lower concentrations of both fibrinolysis in-
hibitors at admission (PAI-1 and TAFI in complicated
cases) might result from increased consumption and lead
to increased fibrinolytic activity due to the procoagulant
state in babesiosis. These biomarkers might be clinically
useful as biomarkers of disease monitoring in babesiosis.
Further studies into their usefulness as biomarkers of
disease severity or prognosis are warranted. Furthermore,
studies of the complex mechanisms linking inflammation,
endothelial dysfunction and hemostatic systems deserve
more attention in veterinary medicine.
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